Electrophysiology in demyelinating polyneuropathies

Expert Review of Neurotherapeutics

Volumn 8, Issue 3, 2008, Pages 417-431

  Franssen, H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; Conduction block; Conduction velocity; Criteria; Demyelination; Excitability; Guillain Barre syndrome; Multifocal motor neuropathy; Nerve conduction; Polyneuropathy

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; RITUXIMAB;

ANTIMYELIN ASSOCIATED GLYCOPROTEIN NEUROPATHY; CHANNEL GATING; DEMYELINATION; ELECTROMYOGRAPHY; ELECTROPHYSIOLOGY; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; GUILLAIN BARRE SYNDROME; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MEMBRANE POTENTIAL; MOTOR NERVE CONDUCTION; MOTOR NEUROPATHY; NERVE BLOCK; NERVE CONDUCTION; NERVE EXCITABILITY; NERVE FIBER MEMBRANE; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; POLYNEUROPATHY; REMYELINIZATION; REVIEW;

AXONS; EVIDENCE-BASED MEDICINE; GUILLAIN-BARRE SYNDROME; ION CHANNELS; MEMBRANE POTENTIALS; MOTOR NEURONS; NEURAL CONDUCTION; PERIPHERAL NERVES;

EID: 41649112380     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.3.417     Document Type: Review

References (89)

1. Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders(2nd Edition). Butterworth-Heinemann, Oxford, UK (2005).
2. Donofrio PD, Albers JW. AAEM minimonograph #34: polyneuropathy: classification by nerve conduction studies and electromyography. Muscle Nerve 13, 889-903 (1990).
3. Van den Berg-Vos RM, Visser J, Franssen H et al. Sporadic lower motor neuron disease with adult onset: classification of subtypes. Brain 126, 1036-1047 (2003).
4. Van den Berg-Vos RM, Franssen H, Wokke JHJ, Van Es HW, Van den Berg LH. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann. Neurol. 48, 919-926 (2000).
5. Van Asseldonk JTH, Van den Berg LH, Van den Berg-Vos RM, Wieneke GH, Franssen H. Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain 126, 186-198 (2003).
6. Cappellari A, Nobile-Orazio E, Meucci N et al. Criteria for early detection of conduction block in multifocal motor neuropathy (MMN): a study based on control populations and follow-up of MMN patients. J. Neurol. 244, 625-630 (1997).
7. Rivner MH, Swift TR, Malik K. Influence of age and height on nerve conduction. Muscle Nerve 24, 1134-1141 (2001).
8. McCluskey L, Feinberg D, Cantor C, Bird S. "Pseudo-conduction block" in vasculitic neuropathy. Muscle Nerve 22, 1361-1366 (1999).
9. Arroyo EJ, Scherer SS. On the molecular architecture of myelinated fibers. Histochem. Cell Biol. 113, 1-18 (2000).
10. Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin. Neurophysiol. 112, 1575-1585 (2001). • Provides an excellent explanation of excitability techniques and ion channel activity in axons.
11. Kaji R. Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies. Muscle Nerve 27, 285-296 (2003). •• Presents overviews of the principles of normal saltatory conduction and the several physiological mechanisms that may induce conduction block.
12. Schwartz JR, Reid G, Bostock H. Action potentials and membrane currents in the human node of Ranvier. Pflugers Arch. 430, 283-292 (1995).
13. Rasminsky M. The effects of temperature on conduction in demyelinated single nerve fibers. Arch. Neurol. 28, 287-292 (1973).
14. Davis FA, Schauf CL, Reed BJ, Kesler RL. Experimental studies of the effects of extrinsic factors on conduction in normal and demyelinated nerve. J. Neurol. Neurosurg. Psychiatr. 39, 442-448 (1975).
15. Schauf CL, Davis FA. Impulse conduction in multiple sclerosis: a theoretical basis for modification by temperature and pharmacological agents. J. Neurol. Neurosurg. Psychiatr. 37, 152-161 (1974).
16. Bergin PS, Miller DH, Hirsch NP, Murray NM. Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann. Neurol. 34, 406-409 (1993).
17. Buchtal F, Behse F. Peroneal muscular atrophy (PMA) and related disorders. I. Clinical manifestations as related to biopsy findings, nerve conduction and electromyography. Brain 100, 41-66 (1977).
18. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41, 617-618 (1991).
19. Logigian EL, Kelly JJ Jr, Adelman LS. Nerve conduction and biopsy correlation in over 100 consecutive patients with suspected polyneuropathy. Muscle Nerve 17, 1010-1020 (1994).
20. Van Asseldonk JTH, Van den Berg LH, Kalmijn S, Wokke JHJ, Franssen H. Criteria for demyelination based on the maximum slowing due to axonal degeneration, determined after warming in water at 37°C: diagnostic yield in chronic inflammatory demyelinating polyneuropathy. Brain 128, 880-891 (2005). • In this investigation, cut-off criteria for demyelination were developed for distal motor latency, motor nerve conduction, F-wave latency and temporal dispersion. The criteria are only applicable at 37•C and are based on the maximal slowing that may occur in axonal degeneration.
21. Thaisetthawatkul P, Logigian EL, Herrmann DN. Dispersion of the distal compound muscle action potentials as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology 59, 1526-1532 (2002).
22. Priori A, Bossi B, Ardolino G et al. Pathophysiological heterogeneity of conduction blocks in multifocal motor neuropathy. Brain 128, 1642-1648 (2005).
23. Kuwabara S, Yuki N, Koga M et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barre syndrome. Ann. Neurol. 44, 202-208 (1998).
24. Tamura N, Kuwabara S, Misawa S et al. Time course of axonal regeneration in acute motor axonal neuropathy. Muscle Nerve 35, 793-795 (2007).
25. Feasby TE, Brown WF, Gilbert JJ, Hahn AF. The pathological basis of conduction block in human neuropathies. J. Neurol. Neurosurg. Psychiatr. 48, 239-244 (1985).
26. Van den Berg-Vos RM, Franssen H, Wokke JHJ, Van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 125, 1875-1886 (2002).
27. Van Asseldonk JTH, Van den Berg LH, Kalmijn S, Van den Berg-Vos RM, Franssen H. Axon loss is an important determinant of weakness in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatr. 77, 743-747 (2006).
28. Rhee EK, England JD, Sumner AJ. A computer simulation of conduction block: effects produced by actual block versus interphase cancellation. Ann. Neurol. 28, 146-156 (1990).
29. Olney RK. Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve 22(Suppl. 8), S225-S229 (1999).
30. Van Asseldonk JTH, Van den Berg LH, Wieneke GH, Wokke JHJ, Franssen H. Criteria for conduction block based on computer simulation studies of nerve conduction with human data obtained in the forearm segment of the median nerve. Brain 129, 2447-2460 (2006). •• Contains a critical discussion of how criteria for conduction block on nerve conduction studies can be derived. It presents a complicated investigation yielding criteria for conduction block based on simulations with human data obtained with surface electrodes.
31. Padua L, Aprile I, D'Amico P et al. A useful electrophysiological test for diagnosis of minimal conduction block. Clin. Neurophysiol. 112, 1041-1048 (2001).
32. Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 23, 399-409 (2000).
33. Cappelen-Smith C, Kuwabara S, Lin CS, Mogyoros I, Burke D. Acrtivity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Ann. Neurol. 48, 826-832 (2000).
34. Kaji R, Bostock H, Kohara N et al. Activity-dependent conduction block in multifocal motor neuropathy. Brain 123, 1602-1611 (2000).
35. Franssen H, Notermans NC, Wieneke GH. The influence of temperature on nerve conduction in patients with chronic axonal polyneuropathy. Clin. Neurophysiol. 110, 933-940 (1999).
36. Franssen H, Wieneke GH, Wokke JHJ. The influence of temperature on conduction block. Muscle Nerve 22, 166-173 (1999).
37. Rutten GJM, Gaasbeek RDA, Franssen H. Decrease in nerve temperature: a model for increased temporal dispersion. Electroenceph. Clin. Neurophysiol. 109, 15-23 (1998).
38. Geerlings AHC, Mechelse K. Temperature and nerve conduction velocity, some practical problems. Electromyogr. Clin. Neurophysiol. 25, 253-260 (1985).
39. Notermans NC, Franssen H, Wieneke GH, Wokke JHJ. Temperature dependence of nerve conduction and EMG in neuropathy associated with gammopathy. Muscle Nerve 17, 516-522 (1994).
40. Franssen H, Wieneke GH. Nerve conduction and temperature: necessary warming time. Muscle Nerve 17, 336-344 (1994).
41. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 366, 1653-1666 (2005).
42. Saida K, Sumner AJ, Saida T et al. Antiserum-mediated demyelination: relationship between remyelination and functional recovery. Ann. Neurol. 8, 12-24 (1980).
43. Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 8, 528-539 (1985).
44. Meulstee J, Van der Meche FG. Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barre syndrome. J. Neurol. Neurosurg. Psychiatr. 59, 482-486 (1995).
45. Hiraga A, Kuwabara S, Ogawara K et al. Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barre syndrome. Neurology 64, 856-860 (2005).
46. Clouston PDE, Kiers L, Zuniga G, Cros D. Quantitative analysis of the compound muscle action potential in early acute inflammatory demyelinating polyneuropathy. Electroenceph. Clin. Neurophysiol. 93, 245-254 (1994).
47. Cornblath DR, Mellits ED, Griffin J et al. Motor conduction studies in Guillain-Barre-syndrome: description and prognostic value. Ann. Neurol. 23, 354-359 (1988).
48. Ho TW, Mishu B, Li CY et al. Guillain-Barre syndrome in northern China. Relationship to Camphylobacter jejuni infection and anti-glycolipid antibodies. Brain 118, 597-605 (1995).
49. Yuki N, Susuki K, Koga M et al., Carbohydrate mimicri between human ganglioside GM1 and Campylobacter jejuni lipoolisaccharide causes Guillain-Barre syndrome. Proc. Natl Acad. Sci. USA 101, 11404-11409 (2004).
50. Capasso M, Caporale CM, Pomilio F et al. Acute motor conduction block neuropathy. Neurology 61, 617-622 (2003).
51. Hirota N, Kaji R, Bostock H et al. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain 120, 2159-2169 (1997).
52. Kuwabara S, Bostock H, Ogawara K et al. The refractory period of transmission is impaired in axonal Guillain-Barre syndrome. Muscle Nerve 28, 683-689 (2003).
53. Susuki K, Rasband MN, Tohyama K et al. Anti-GM-1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J. Neurosci. 27, 3956-3967 (2007).
54. Hughes RAC, Bouche P, Cornblath DR et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyneuropathy. Eur. J. Neurol. 13, 326-332 (2006).
55. Molenaar DSM, Vermeulen M, De Haan R. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatr. 64, 84-89 (1998).
56. Nicolas G, Maisonobe T, Le Forestier N, Léger JM, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 25, 26-30 (2002).
57. Magda P, Latov N, Brannagan III TH et al. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch. Neurol. 60, 1755-1759 (2003).
58. Latov N. Diagnosis of CIDP. Neurology 59, S2-S6 (2002). •• Critical discussion of the clinical usefulness of electrophysiological criteria sets for the diagnosis of chronic inflammatory polyneuropathy.
59. Molenaar DSM, Vermeulen M, De Haan RJ. Comparison of electrodiagnostic criteria for demyelination in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). J. Neurol. 249, 400-403 (2002).
60. Sharma K, Cross J, Farronay O et al. Demyelinating neuropathy in diabetes mellitus. Arch. Neurol. 59, 758-765 (2002).
61. Rosenberg NR, Portegies P, De Visser M, Vermeulen M. Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline. J. Neurol. Neurosurg. Psychiatr. 71, 205-209 (2001).
62. Lozeron P Nahum L, Lacroix C et al. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J. Neurol. 249, 569-575 (2002).
63. Sung J, Kuwabara S, Kaji R et al. Threshold electrotonus in chronic inflammatory demyelinating polyneuropathy: correlation with clinical profiles. Muscle Nerve 29, 28-37 (2004).
64. Van Dijk GW, Notermans NC, Franssen H, Wokke JHJ. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a longterm follow-up study. J. Neurol. 246, 1134-1139 (1999).
65. Chin RL, Latov N, Sander HW et al. Sensory CIDP presenting as cryptogenic sensory polyneuropathy. J. Peripher. Nerv. Syst. 9, 132-137 (2004).
66. Sinnreich M, Klein CJ, Daube JR et al. Chronic immune sensory polyradiculopathy. Neurology 63, 1662-1669 (2004).
67. Hughes RAC, Bouche P, Cornblath DR et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. J. Peripher. Nerv. Syst. 11, 1-8 (2006).
68. Katz JS, Barohn RJ, Kojan S et al. Axonal multifocal motor neuropathy without conduction block or other features of demyelination. Neurology 58, 615-620 (2002).
69. Kiernan MC, Guglielmi JM, Kaji R, Murray NMF, Bostock H. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 125, 664-675 (2002).
70. Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nature Rev. 7, 932-941 (2006).
71. Van den Berg-Vos RM, Van den Berg LH, Franssen H et al. Multifocal inflammatory demyelinating neuropathy. A distinct clinical entity? Neurology 54, 26-32 (2000).
72. Steck AJ, Stalder AK, Renaud S. Antimyelin-associated glycoprotein neuropathy. Curr. Opin. Neurol. 19, 458-463 (2006).
73. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 117, 941-947 (1994).
74. Franssen H, Notermans NC. Lengthdependence in polyneuropathy associated with IgM gammopathy. Ann. Neurol. 59, 365-371 (2006). • Investigation showing that distal nerve conduction slowing in IgM-related neuropathies is more prominent for nerves with longer axons. The possible mechanisms for this unique lengthdependence, which does not occur in chronic inflammatory demyelinating polyneuropathy, are discussed.
75. Lombardi R, Erne B, Lauria G et al. IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy. Ann. Neurol. 57, 180-187 (2005).
76. Lunn MPT, Crawford TO, Hughes RAC, Griffin JW, Sheikh KA. Anti-myelin associated glycoprotein antibodies alter neurofilament spacing. Brain 125, 904-911 (2002).
77. Sung J, Kuwabara S, Ogawara K et al. Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle Nerve 26, 189-193 (2002).
78. Krajewski KM, Lewis RA, Fuerst DR et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 123, 1516-1527 (2000).
79. Devaux JJ, Scherer SS. Altered ion channels in an animal model of Charcot-Marie-Tooth disease type 1A. J. Neurosci. 25, 1470-1480 (2005).
80. Rush AM, Cummins TR, Waxman SG. Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons. J. Physiol. 579, 1-14 (2007).
81. Bai Y, Ianokova E, Pu Q et al. Effect of an R69C mutation in the myelin protein zero gene on myelination and ion channel subtypes. Arch. Neurol. 63, 1787-1794 (2006).
82. Li J, Krajewski K, Shy ME, Lewis RA. Hereditary neuropathy with liability to pressure palsy. The electrophysiology fits the name. Neurology 58, 1769-1773 (2002).
83. Suter U, Scherer SS. Disease mechanisms in inherited neuropathies. Nat. Rev. Neurosci. 4, 714-726 (2003).
84. Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ. Blockers of sodium and calcium entry protect motor axons from nitric oxide-mediated degeneration. Ann. Neurol. 53, 174-180 (2003). • In an animal model of inflammatory demyelination, conduction block and axonal degeneration were induced by sustained nerve activity. By pharmacological Nachannel and Na/Ca-exchanger modification, axonal degeneration was prevented.
85. Watson DF, Nachtman FN, Kuncl RW, Griffin JW. Altered neurofilament phosphorylation and beta tubulin isotypes in Charcot-Marie-Tooth disease type 1. Neurology 44, 2383-2387 (1994).
86. Fabrizi GM, Simonati A, Morbin M et al. Cli nical and pathological correlations in Charcot-Marie-Tooth neuropathy type 1a with the 17p11.2p12 duplication: a cross-sectional morphometric and immunohistochemical study in twenty cases. Muscle Nerve 21, 869-877 (1998).
87. Grandis M, Leandri M, Vigo T et al. Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. Exp. Neurol. 190, 213-223 (2004).
88. Bostock H, Sears TA. Continuous conduction in demyelinated mammalian nerve fibers. Nature 263, 786-787 (1976).
89. Goldfarb AR, Latov N, Brannagan TH et al. Correlation of demyelinating and clinical features in patients with neuropathy of otherwise unknown etiology. Neurol. Neurophysiol. Neurosci. 7, 1-9 (2006).